You are here

Sublingual Sufentanil Reduces Postoperative Pain in Phase III Study

PCA drug/device candidate is currently under FDA review

Positive results have been reported from a phase III trial evaluating the safety and efficacy of Zalviso (AcelRx Pharmaceuticals) –– also known as the sufentanil sublingual tablet system (SSTS) –– for the treatment of moderate-to-severe postoperative pain after major joint-replacement surgery. The findings were published in the June 2015 issue of Anesthesiology.

Zalviso is an investigational patient-controlled analgesia (PCA) drug/device candidate currently under review by the FDA.

The randomized, double-blind, placebo-controlled study met its primary endpoint, demonstrating that SSTS (15 mcg) was significantly better at managing pain over 48 hours, as measured by Summed Pain Intensity Difference to Baseline (SPID-48), than placebo (P < 0.001). The SPID-48 score was 76 for SSTS compared with –11 for placebo, for a difference of 88. SSTS-treated patients had pain relief scores superior to those of placebo-treated patients within 45 minutes after study initiation.

Reports of treatment-related adverse events were similar between the two groups, with the exception of nausea and itching, which were more common in the SSTS group. Fewer SSTS-treated patients withdrew from the study because of inadequate analgesia compared with placebo-treated patients (14% vs. 48%, respectively; P < 0.001). In addition, the SSTS group used approximately half as much rescue morphine over the duration of the trial compared with the placebo group (2.3 doses vs. 4.0 doses, respectively).

As a secondary endpoint, a validated ease-of-care questionnaire was administered to patients and health care providers. Both groups gave SSTS a total overall rating above 4 on a scale of 0 to 5.

The authors concluded that SSTS may integrate well with a multimodal approach to acute pain management in the hospital setting.

Sources: AcelRx Pharmaceuticals; July 2, 2015; and Anesthesiology; June 2015.


Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug